Loading...
Indian Pharmaceutical Exporter · #5 for Clarithromycin · $2.1M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Clarithromycin with $2.1M in export value and 43 verified shipments. Cipla Limited holds a 2.2% market share in Clarithromycin exports across 6 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| 2 |
| 1.1% |
| TANZANIA | $4.0K | 1 | 0.4% |
Cipla Limited exports Clarithromycin to 6 countries. The largest destination is UGANDA accounting for 49.5% of Cipla Limited's Clarithromycin shipments, followed by KENYA (30.1%) and TURKEY (14.5%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ABACUS PHARMA LTD | UGANDA | $384.3K | 13 |
| CIPLA KENYA LTD C/O IMPERIAL | KENYA | $241.3K | 9 |
| HIGEN COMPANY | TURKEY | $164.2K | 6 |
| ABACUS PHARMA LIMITED | UGANDA | $117.4K | 6 |
| CIPLA KENYA LTD C/O IMPERIAL MANAGE | KENYA | $100.0K | 2 |
| CIPLA QUALITY CHEMICAL INDUSTRIES | UGANDA | $59.5K | 3 |
| PRIME PHARMACEUTICALS LIMITED | ZAMBIA | $50.0K | 1 |
| SOMAPHAR SA | MADAGASCAR | $9.2K | 1 |
| JD PHARMACY | TANZANIA | $4.0K | 1 |
| OPHAM | MADAGASCAR | $3.5K | 1 |
Cipla Limited supplies Clarithromycin to 10 buyers globally. The largest buyer is ABACUS PHARMA LTD (UGANDA), followed by CIPLA KENYA LTD C/O IMPERIAL (KENYA) and HIGEN COMPANY (TURKEY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $61.2M worth of Clarithromycin through 3,576 shipments from 334 suppliers to 144 countries, serving 811 buyers globally. Cipla Limited contributes $2.1M to this total, accounting for 2.2% of India's Clarithromycin exports. Cipla Limited ships Clarithromycin to 6 countries through 10 buyers.
Cipla Limited's average Clarithromycin shipment value is $50.0K per consignment, based on 43 shipments totaling $2.1M. The largest destination is UGANDA (49.5% of Cipla Limited's Clarithromycin exports).
Cipla Limited ranks #5 among 334 Indian Clarithromycin exporters with a 2.2% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($15.4M), MICRO LABS LIMITED ($15.4M), AUROBINDO PHARMA LTD ($7.8M). Cipla Limited processed 43 shipments to 6 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS 250MG KIT) | $150.0K | 3 |
| ESCLAM KIT(AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG & ESOMEPRAZOLE 20MG DR TABLETS)[PS:7X1X6X10100PAC=424200 NOS] | $100.0K | 2 |
| ESCLAM KIT (AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG AND ESOMEPRAZOLE 20MG DR TABLETS) [19840(PACKS)X7X1X6'S]NOS | $72.0K | 3 |
| ESCLAM KIT (AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG AND ESOMEPRAZOLE 20MG DR TABLETS) [17280(PACKS)X7X1X6'S]NOS | $63.7K | 3 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS250MG KIT) (7 X 1 X 6S(2+2+2) (11970 PANOS | $58.7K | 3 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS250MG KIT) (7 X 1 X 6S(2+2+2) (11965 PANOS | $58.7K | 3 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS 250MG KIT) [10584(PACKS)X7X1X6'S] | $54.4K | 3 |
| PYLOKIT LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TAB.500MG+CLARITHROMYCIN TAB.250MG KIT12096PACKSX7X1X6=508032NOS 2+2+2 | $50.0K | 1 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS 250MG KIT) [52653(PACKS)X7X1X6'S] | $50.0K | 1 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS 250MG KIT) [52920(PACKS)X7X1X6'S] | $50.0K | 1 |
Cipla Limited exports 28 distinct Clarithromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLA with 3 shipments worth $150.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | AJANTA PHARMA LIMITED | $4.0M | 109 | 9 | $36.6K |
| 10 | IND SWIFT LIMITED | $2.9M | 124 | 23 | $23.0K |
| 5 | CIPLA LIMITED ★ | $2.1M | 43 | 6 | $50.0K |
| 6 | WEXFORD LABORATORIES PRIVATE LIMITED | $1.8M | 35 | 4 | $50.0K |
| 9 | AUROBINDO PHARMA LIMITED | $1.8M | 35 | 3 | $50.0K |
Cipla Limited ranks #5 among 334 Indian Clarithromycin exporters. Average shipment value of $50.0K compared to the market average of $183.3K. The closest competitors by value are AJANTA PHARMA LIMITED and IND SWIFT LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 365 | 10.2% |
| DELHI AIR CARGO ACC (INDEL4) | 296 | 8.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 282 | 7.9% |
| DELHI AIR | 258 | 7.2% |
| NHAVA SHEVA SEA (INNSA1) | 229 | 6.4% |
| JNPT/ NHAVA SHEVA SEA | 156 | 4.4% |
| JNPT | 125 | 3.5% |
| DHANNAD ICD | 124 | 3.5% |
Visual overview of India's clarithromycin supplier profile for Cipla Limited — top suppliers, destinations, pricing, and trade routes
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Clarithromycin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Clarithromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 144+ countries, 811+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Clarithromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clarithromycin. For current shipment-level data, contact TransData Nexus.